5P evidence-based medicine and clinical protocols
Scientific evidence base for medical modalities: NCBI PubMed studies, meta-analyses and RCTs with CEBM (Oxford) levels of evidence, biological mechanisms of action (MoA) and clinical protocols across 9 axes of preventive medicine (M0–M8).
NCBI PubMed & PMC
Meta-analyses and RCTs
Regimens and dosages
Modules M0–M8
| PMID / Year | Publication and journal | 5P axis / Modality | CEBM level | Primary source |
|---|
9 fundamental axes of integrative 5P medicine
A systematised architecture of wellness interventions: each module covers a key link of homeostasis, targeted longevity biomarkers, physiotherapy devices and validated clinical protocols.
Interactive Ganzoni calculator
5P OptimumClinical status and dosage calculation
Latent iron deficiency (IDWA)Recommended 5P preventive correction strategy:
Values are within the formal laboratory reference range but below the preventive longevity optimum (>50-100 µg/L). An alternate-day regimen is recommended: iron bisglycinate 25 mg every other day on an empty stomach with vitamin C (100 mg), plus cofactors (copper, methylfolate).
Bioenergetics calculator (L:P & VO2 max)
Axis M3Mitochondrial status assessment
Subclinical dysfunctionRecommended device and nutraceutical protocol (Axis M3):
Differential diagnosis tree of root causes
An interactive algorithm that identifies the leading aetiological factor and selects a targeted work-up plan.
No significant aggravating factors selected
Tick symptoms and history on the left to estimate the probability of aetiological factors.
Comparative biomarker matrix: Laboratory reference range vs 5P Optimum
Industry benchmark of preventive medicine for detecting subclinical depletion of reserves
| Biomarker | Standard laboratory reference range | 5P medicine target optimum | Clinical rationale for the optimum |
|---|---|---|---|
| Serum ferritin | 10 – 120 µg/L | > 50 – 100 µg/L (≈ body weight in kg) | Below 50 µg/L, the activity of mitochondrial respiratory chain cytochromes declines. |
| Transferrin saturation (TSAT) | > 15 % | > 25 – 35 % | A key marker of the available circulating iron pool, independent of the hepcidin block. |
| Haemoglobin (Hb) | >120 g/L (f) / >130 g/L (m) | 125 – 140 g/L (f) / 140 – 160 g/L (m) | Optimal blood oxygen-carrying capacity without hyperviscosity risks. |
| Mean corpuscular volume (MCV) | 80 – 100 fL | > 85 – 92 fL | A drop below 85 fL even with normal Hb indicates latent microcytosis. |
| High-sensitivity CRP (hs-CRP) | < 5.0 mg/L | < 0.8 – 1.0 mg/L | Rules out low-grade inflammation (inflammaging) and hepcidin blockade of ferroportin. |
| Resting plasma lactate | 0.5 – 2.2 mmol/L | < 1.2 – 1.5 mmol/L | An increase at rest indicates an anaerobic glycolytic shift and insufficient pyruvate dehydrogenase activity. |
| Lactate / pyruvate ratio (L:P) | 10:1 – 20:1 | 10:1 – 15:1 | Reflects the NADH/NAD+ redox balance. Values >20:1 are validated as a sign of Complex I-IV defects (Smet et al., 2015). |
| Plasma coenzyme Q10 (ubiquinone) | 0.5 – 1.0 mg/L | > 1.5 – 2.0 mg/L | A key lipophilic electron carrier in Complex III and protector of cardiolipin against lipid peroxidation. |
| Cardiorespiratory optimum VO2 max | > 20 – 25 mL/kg/min | > 35 – 45 mL/kg/min (by age) | The gold-standard industry benchmark of tissue aerobic capacity and longevity. A deficit >15% indicates oxidative uncoupling. |
| Urinary 8-OHdG (DNA oxidation) | < 10.0 ng/mg creatinine | < 4.0 – 5.0 ng/mg creatinine | Marker of direct oxidative damage by free radicals to guanine bases of mitochondrial DNA (mtDNA). |
Key evidence studies of the specification (Landmark Evidence)
Included RCTs, meta-analyses and consensus guidelines with CEBM levels by study design